Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ANB033 single and multiple doses
NL-OMON59598Phase 1Recruiting
- Sponsor
- First Tracks Biotherapeutics
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of ANB033 in celiac disease and eosinophilic esophagitis (EoE), sponsored by First Tracks Biotherapeutics. Started Nov 2025; status: recruiting.
02
Drugs
ANB033
03
Conditions
celiac diseaseeosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON59598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59598.